Patents by Inventor Michael S. KAPILOFF

Michael S. KAPILOFF has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of heart disease by disruption of the anchoring of PP2A
    Patent number: 11938198
    Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: March 26, 2024
    Assignees: University of Miami, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael S. Kapiloff, Jinliang Li
  • Compositions for treating heart disease by inhibiting the action of mAKAP-?
    Patent number: 11931402
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: January 21, 2022
    Date of Patent: March 19, 2024
    Inventors: Michael S. Kapiloff, Jinliang Li, Michael Kritzer
  • COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-beta
    Publication number: 20220143138
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Application
    Filed: January 21, 2022
    Publication date: May 12, 2022
    Applicant: Anchored RSK3 Inhibitors, LLC
    Inventors: Michael S. KAPILOFF, Jinliang LI, Michael KRITZER
  • TARGETING OF MAKAP-PDE4D3 COMPLEXES IN NEURODEGENERATIVE DISEASE
    Publication number: 20220041667
    Abstract: Nervous system trauma and neurodegeneration including in optic neuropathies are treated by administration of an effective dose of a PDE4D3 displacing agent to promote neurite extension, neuroprotection and recovery. In some embodiments the neurons are optic neurons, including without limitation retinal ganglion cells (RGCs). A cAMP signaling compartment restricted by mAKAP?-anchored PDE4D3 directly regulates neuronal phenotype, and can be molecularly manipulated with therapeutic effect.
    Type: Application
    Filed: November 13, 2019
    Publication date: February 10, 2022
    Inventors: Michael S. Kapiloff, Jeffrey L. Goldberg
  • Compositions for treating heart disease by inhibiting the action of mAKAP?
    Patent number: 11229679
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: January 25, 2022
    Assignee: ANCHORED RSK3 INHIBITORS, LLC
    Inventors: Michael S. Kapiloff, Jinliang Li, Michael Kritzer
  • Treatment of heart disease by inhibtion of the action of muscle A-kinase anchoring protein (mAKAP)
    Patent number: 10907153
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition is preferably in the form of an siRNA construct, more preferably an shRNA construct, which inhibits the expression of mAKAP?.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: February 2, 2021
    Inventor: Michael S. Kapiloff
  • TREATMENT OF HEART DISEASE BY DISRUPTION OF THE ANCHORING OF PP2A
    Publication number: 20200360536
    Abstract: The present invention provides a method of treating heart failure with reduced ejection fraction, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the anchoring of PP2A to mAKAP?. This composition is preferably in the form of a viral based gene therapy vector that encodes a fragment of mAKAP? to which PP2A binds.
    Type: Application
    Filed: March 13, 2020
    Publication date: November 19, 2020
    Applicants: University of Miami, The Board of Trustees of the Leland Stanford Junior University
    Inventors: Michael S. KAPILOFF, Jinliang LI
  • COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-beta
    Publication number: 20200289615
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Application
    Filed: April 1, 2020
    Publication date: September 17, 2020
    Applicant: Anchored RSK3 Inhibitors, LLC
    Inventors: Michael S. KAPILOFF, Jinliang LI, Michael KRITZER
  • Compositions for treating heart disease by inhibiting the action of mAKAP-?
    Patent number: 10617737
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: April 14, 2020
    Assignee: Anchored RSK3 Inhibitors, LLC
    Inventors: Michael S. Kapiloff, Jinliang Li, Michael Kritzer
  • TREATMENT OF HEART DISEASE BY INHIBTION OF THE ACTION OF MUSCLE A-KINASE ANCHORING PROTEIN (mAKAP)
    Publication number: 20190010493
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition is preferably in the form of an siRNA construct, more preferably an shRNA construct, which inhibits the expression of mAKAP?.
    Type: Application
    Filed: July 5, 2018
    Publication date: January 10, 2019
    Inventor: Michael S. KAPILOFF
  • COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-ß
    Publication number: 20180296638
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Application
    Filed: April 5, 2018
    Publication date: October 18, 2018
    Applicant: Anchored RSK3 Inhibitors, LLC
    Inventors: Michael S. KAPILOFF, Jinliang LI, Michael KRITZER, Catherine PASSARIELLO, Kimberly DODGE-KAFKA
  • Treatment of myocardial infarction by inhibiting the action of mAKAP?
    Patent number: 9937228
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: August 7, 2015
    Date of Patent: April 10, 2018
    Assignee: ANCHORED RSK3 INHIBITORS, LLC
    Inventors: Michael S Kapiloff, Jinliang Li, Michael Kritzer, Catherine Passariello, Kimberly Dodge-Kafka
  • TREATMENT OF HEART DISEASE BY INHIBITION OF THE ACTION OF RIBOSOMAL S6 KINASE 3 (RSK3)
    Publication number: 20160038568
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Application
    Filed: August 7, 2015
    Publication date: February 11, 2016
    Applicant: Anchored RSK3 Inhibitors, LLC
    Inventors: Michael S. KAPILOFF, Jinliang Li, Michael Kritzer, Catherine Passariello, Kimberly Dodge-Kafka
  • Treatment of heart disease by inhibition of the action of ribosomal S6 kinase 3 (RSK3)
    Patent number: 9132174
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: September 15, 2015
    Assignee: Anchored RSK3 Inhibitors, LLC
    Inventors: Michael S Kapiloff, Jinliang Li, Michael Kritzer, Catherine Passariello, Kimberly Dodge-Kafka
  • TREATMENT OF HEART DISEASE BY INHIBITION OF THE ACTION OF RIBOSOMAL S6 KINASE 3 (RSK3)
    Publication number: 20140286928
    Abstract: The present invention provides a method of protecting the heart from damage, by administering to a patient at risk of such damage, a pharmaceutically effective amount of a composition which inhibits the interaction of RSK3 and mAKAP?, or the expression or activity of one or both of those molecules. This composition may be in the form of a peptide that specifically inhibits mAKAP? binding to RSK3 or in the form of an siRNA construct which inhibits the expression of RSK3.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 25, 2014
    Applicant: ANCHORED RSK3 INHIBITORS, LLC
    Inventors: Michael S. KAPILOFF, Jinliang LI, Michael KRITZER, Catherine PASSARIELLO, Kimberly DODGE-KAFKA